272 related articles for article (PubMed ID: 19476018)
1. Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases.
Dashti-Khavidaki S; Aghamohammadi A; Farshadi F; Movahedi M; Parvaneh N; Pouladi N; Moazzami K; Cheraghi T; Mahdaviani SA; Saghafi S; Heydari G; Abdollahzade S; Rezaei N
J Investig Allergol Clin Immunol; 2009; 19(2):139-45. PubMed ID: 19476018
[TBL] [Abstract][Full Text] [Related]
2. Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency.
Aghamohammadi A; Farhoudi A; Nikzad M; Moin M; Pourpak Z; Rezaei N; Gharagozlou M; Movahedi M; Atarod L; Afshar AA; Bazargan N; Hosseinpoor AR
Ann Allergy Asthma Immunol; 2004 Jan; 92(1):60-4. PubMed ID: 14756466
[TBL] [Abstract][Full Text] [Related]
3. Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions.
Bichuetti-Silva DC; Furlan FP; Nobre FA; Pereira CT; Gonçalves TR; Gouveia-Pereira M; Rota R; Tavares L; Mazzucchelli JT; Costa-Carvalho BT
Int Immunopharmacol; 2014 Dec; 23(2):442-6. PubMed ID: 25257732
[TBL] [Abstract][Full Text] [Related]
4. Adverse reactions in a large cohort of patients with inborn errors of immunity receiving intravenous immunoglobulin.
Esmaeilzadeh H; Askarisarvestani A; Hosseini N; Samimi S; Shafiei A; Mahdaviani SA; Eslami N; Chavoshzadeh Z; Fallahi M; Khakbazanfard N; Shabestari MS; Aleyasin S; Nabavizadeh SH; Cheraghi T; Kalantari A; Ahmadiafshar A; Safari M; Eslamian MH; Molatefi R; Shirkani A; Heidarzadeh Arani M; Tavakol M; Bemanian MH; Arshi S; Nabavi M; Shokri S; Shahhosseini B; Mortazavi N; Nakhaei P; Nazari F; Fallahpour M; Ahanchian H; Moazzen N; Khoshkhui M; Motlagh AV; Aghamohammadi A; Abolhassani H; Yazdani R; Rezaei N
Clin Immunol; 2021 Sep; 230():108826. PubMed ID: 34418548
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.
Jolles S; Bernatowska E; de Gracia J; Borte M; Cristea V; Peter HH; Belohradsky BH; Wahn V; Neufang-Hüber J; Zenker O; Grimbacher B
Clin Immunol; 2011 Oct; 141(1):90-102. PubMed ID: 21705277
[TBL] [Abstract][Full Text] [Related]
6. Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections.
Günther G; Dreger B
Microbiol Immunol; 2013 Jul; 57(7):527-35. PubMed ID: 23607863
[TBL] [Abstract][Full Text] [Related]
7. Intrainfusion and postinfusion adverse events related to intravenous immunoglobulin therapy in immunodeficiency states.
Tcheurekdjian H; Martin J; Kobayashi R; Wasserman R; Hostoffer R
Allergy Asthma Proc; 2006; 27(6):532-6. PubMed ID: 17176791
[TBL] [Abstract][Full Text] [Related]
8. Immune globulin (human) 10 % liquid: a review of its use in primary immunodeficiency disorders.
McCormack PL
BioDrugs; 2013 Aug; 27(4):393-400. PubMed ID: 23703447
[TBL] [Abstract][Full Text] [Related]
9. Adverse reactions of intravenous immunoglobulin.
Al-Wahadneh AM; Khriesat IA; Kuda EH
Saudi Med J; 2000 Oct; 21(10):953-6. PubMed ID: 11369961
[TBL] [Abstract][Full Text] [Related]
10. Adverse reactions and influencing factors in children with primary immunodeficiencies receiving intravenous immunglobulin replacement.
Ibis IBP; Erdur B; Erdem SB; Karaman S; Gulez N; Genel F
Allergol Immunopathol (Madr); 2020; 48(6):738-744. PubMed ID: 32703652
[TBL] [Abstract][Full Text] [Related]
11. Use of intravenous immunoglobulin to prevent or treat infections in persons with immune deficiency.
Lee ML; Gale RP; Yap PL
Annu Rev Med; 1997; 48():93-102. PubMed ID: 9046948
[TBL] [Abstract][Full Text] [Related]
12. Immediate adverse reactions to intravenous immunoglobulin in primary immune deficiencies: a single center experience.
Nain E; Kıykım A; Kasap NA; Barış S; Özen A; Aydıner EK
Turk J Pediatr; 2020; 62(3):379-386. PubMed ID: 32558411
[TBL] [Abstract][Full Text] [Related]
13. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study.
Debes A; Bauer M; Kremer S
Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):1038-47. PubMed ID: 17636556
[TBL] [Abstract][Full Text] [Related]
14. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies.
Orange JS; Grossman WJ; Navickis RJ; Wilkes MM
Clin Immunol; 2010 Oct; 137(1):21-30. PubMed ID: 20675197
[TBL] [Abstract][Full Text] [Related]
15. Behavior abnormality following intravenous immunoglobulin treatment in patients with primary antibody deficiencies.
Saroukhani S; Aghamohammadi A; Mahmoudi-Gharaei J; Abolhassani H; Cheraghi T; Imanzaeh A; Moazzami K; Parvaneh N; Rezaei N
Hum Psychopharmacol; 2010 Jul; 25(5):419-22. PubMed ID: 20589928
[TBL] [Abstract][Full Text] [Related]
16. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G.
Berger M; Murphy E; Riley P; Bergman GE;
South Med J; 2010 Sep; 103(9):856-63. PubMed ID: 20689467
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of adverse events when changing intravenous immunoglobulin preparations.
Ameratunga R; Sinclair J; Kolbe J
Clin Exp Immunol; 2004 Apr; 136(1):111-3. PubMed ID: 15030521
[TBL] [Abstract][Full Text] [Related]
18. Immunoglobulin treatment in primary antibody deficiency.
Maarschalk-Ellerbroek LJ; Hoepelman IM; Ellerbroek PM
Int J Antimicrob Agents; 2011 May; 37(5):396-404. PubMed ID: 21276714
[TBL] [Abstract][Full Text] [Related]
19. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study.
Gardulf A; Nicolay U; Asensio O; Bernatowska E; Böck A; Carvalho BC; Granert C; Haag S; Hernández D; Kiessling P; Kus J; Pons J; Niehues T; Schmidt S; Schulze I; Borte M
J Clin Immunol; 2006 Mar; 26(2):177-85. PubMed ID: 16758340
[TBL] [Abstract][Full Text] [Related]
20. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy.
Chapel HM; Spickett GP; Ericson D; Engl W; Eibl MM; Bjorkander J
J Clin Immunol; 2000 Mar; 20(2):94-100. PubMed ID: 10821460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
